Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PURO - An Open-label, Randomised, Multicentre, Phase II Study to Evaluate the Efficacy of Chemotherapy With Gemcitabine and Cisplatin in Combination With the EGF Receptor Antibody Panitumumab (GemCisP) Versus GemCis in the First-line Therapy of Locally Advanced/Metastatic Urothelial Carcinoma in Patients With Wild-type HRAS

NCT01374789 is registered in ClinicalTrials.gov with WiSP Wissenschaftlicher Service Pharma GmbH as lead sponsor.

NCT NCT01374789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01374789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PURO - An Open-label, Randomised, Multicentre, Phase II Study to Evaluate the Efficacy of Chemotherapy With Gemcitabine and Cisplatin in Combination With the EGF Receptor Antibody Panitumumab (GemCisP) Versus GemCis in the First-line Therapy of Locally Advanced/Metastatic Urothelial Carcinoma in Patients With Wild-type HRAS
Lead sponsor
WiSP Wissenschaftlicher Service Pharma GmbH
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2010
Completion date
March 31, 2012
Enrollment
2 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder cancer